New DNA Therapy Proves Safe in Type 1 Diabetes Patients—Early Results Open Door to Further Testing

Researchers developed a therapy using plasmid DNA—a small, circular piece of genetic material that does not integrate into cells. The plasmid was engineered to instruct cells to make three things: preproinsulin (PPI), an antigen central to Type 1 diabetes; and three immune-regulating proteins called TGF-β1, IL-10, and IL-2.

The logic behind this approach is antigen-specific tolerance: by introducing the very antigen the immune system attacks, alongside regulatory signals, the therapy aims to teach the immune system to stop targeting insulin-producing cells.

This study enrolled 47 adults with stage 3 Type 1 diabetes (diagnosed disease with some remaining beta cell function). It was placebo-controlled and double-masked, meaning neither participants nor researchers knew who received active treatment.

Phase I trials are designed first and foremost to establish safety and tolerability. The findings were reassuring: most adverse events were Grade 1 (mild), and there was no clinically meaningful difference between the treatment and placebo groups.

Importantly, the researchers found no untoward metabolic or immune effects—meaning no unexpected harm to how the body processes glucose or how the immune system functions overall.

These results suggest the plasmid therapy can be given to patients without raising serious safety red flags, a necessary first step before testing whether it actually helps.

The researchers looked for pharmacodynamic evidence—measurable signs that the drug was doing something in the body. They found a dose-dependent type 1 interferon signature, an immune marker that increased with higher doses. Plasmid DNA was also detected in participants receiving the two highest doses, confirming the genetic material reached systemic circulation.

However, the trial did not show global or antigen-specific immune cell changes following treatment. The researchers did not detect immune alterations driven by the therapeutic proteins IL-2, IL-10, or TGF-β1.

This finding is important: while safety was proven and biological activity was detected, the mechanism by which tolerance might be induced remains unclear. This sets the stage for better-designed follow-up trials with clearer immunological endpoints.

These Phase I results support moving forward with additional trials to test this novel tolerizing antigen construct. The next step typically involves larger studies with longer follow-up to evaluate whether the therapy slows the decline of beta cell function or delays disease progression.

The antigen-specific approach is distinct from immunosuppressive therapies already in use. Rather than broadly damping immune function, this strategy attempts to reprogram the immune response to be tolerant of insulin—a goal that has motivated research for decades.

Much work remains to understand whether this particular formulation and dosing can achieve that goal, and how it might best be combined with other therapies. But the safety signal here is a meaningful first step.

Source: Diabetes. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.